Market Place
Sourcing Support
All News #Library
Biotech
CSL`s Hemgenix In `Temporary Global Stockout,` Company Says
19 Mar 2026 //
FIERCE PHARMA
CSL firms up details on $1.5B US plasma-based medicines plant
11 Mar 2026 //
FIERCE PHARMA
CSL Signs Licensing Deal with Eli Lilly for Clazakizumab
17 Feb 2026 //
REUTERS
NEJM Publishes Five-Year Durability and Safety Data for HEMGENIX
07 Dec 2025 //
PR NEWSWIRE
CSL Earmarks $1.5B For US Production Expansion Over Next 5 Years
18 Nov 2025 //
REUTERS
CSL Behring, pCPA Sign LOI For HEMGENIX Gene Therapy In Hem B
07 Oct 2025 //
PHARMIWEB
CSL Behring`s First Commercial Pitches Hizentra for PI Patients
21 May 2025 //
FIERCE PHARMA
As Pfizer bows out, CSL keeps hemophilia gene therapy hopes alive
12 Apr 2025 //
FIERCE PHARMA
CSL`s Andembry S.C. Injection Approved In Japan For HAE
20 Feb 2025 //
PR NEWSWIRE
EMA Approves CSL`s Andembry® for Hereditary Angioedema
13 Feb 2025 //
PR NEWSWIRE
CSL Behring’s Hemgenix® Shows Sustained Efficacy in Hemophilia B
07 Feb 2025 //
PR NEWSWIRE
First Patients Treated With Hemgenix Therapy For Haemophilia B
21 Jan 2025 //
PHARMAWEB
CSL`s Garadacimab Approved By CHMP For Hereditary Angioedema
13 Dec 2024 //
PR NEWSWIRE
CSL Behring shuts down California cell and gene therapy R&D site
19 Nov 2024 //
FIERCE BIOTECH
CSL Behring Treats First European Patients With HEMGENIX Gene Therapy
04 Jul 2024 //
GLOBENEWSWIRE
Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit
20 Mar 2024 //
FIERCE PHARMA
CSL and uniQure unveil three-year data for one-time hemophilia B gene therapy
09 Feb 2024 //
ENDPTS
FDA, EMA accept Pfizer`s hemophilia B gene therapy
27 Jun 2023 //
ENDPTS
CSL doses first patient with haemophilia B gene therapy Hemgenix
21 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX
20 Jun 2023 //
PR NEWSWIRE
New CEO Paul McKenzie plots CSL`s course for growth
03 Apr 2023 //
FIERCE PHARMA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.